Douglas Tsao analyst

Currently out of the existing stock ratings of Douglas Tsao, 496 are a BUY (83.36%), 4 are a SELL (0.67%), 95 are a HOLD (15.97%).

Douglas Tsao

Work Performance Price Targets & Ratings Chart

Analyst Douglas Tsao, carries an average stock price target met ratio of 44.25% that have a potential upside of 31.15% achieved within 214 days. Previously, Douglas Tsao worked at HC WAINWRIGHT.

Douglas Tsao’s has documented 1,122 price targets and ratings displayed on 50 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on EOLS, Evolus at 09-Jan-2026.

Wall Street Analyst Douglas Tsao

Analyst best performing recommendations are on PRAX (PRAXIS PRECISION MEDICINES ).
The best stock recommendation documented was for ALKS (ALKERMES PLC) at 10/26/2017. The price target of $50 was fulfilled within 1 day with a profit of $4.97 (9.04%) receiving and performance score of 90.41.

Average potential price target upside

CHMA Chiasma MYL Viatris JAZZ Jazz Pharmaceuticals PLC MNK Mallinckrodt plc PCRX Pacira Pharmaceuticals TEVA Teva Pharma Industries Ltd ADR AGN Allergan plc ALKS Alkermes Plc CERE Cerevel Therapeutics Holdings CHRS Coherus BioSciences CRL Charles River Laboratories CRNX Crinetics Pharmaceuticals ENDP Endo International PLC EOLS Evolus IMVT Immunovant  MNTA Momenta Pharmaceuticals OSMT Osmotica Pharmaceuticals plc PRAX Praxis Precision Medicines  PRGO Perrigo Company PLC PTGX Protagonist Therapeutics RDUS Schnitzer Steel Industries RVNC Revance The SAGE Sage Therapeutic ROIV Roivant Sciences Ltd TBPH Theravance Biopharma TRVN Trevena TXMD TherapeuticsMD ARGX argenx NV ADR AMYT Amryt Pharma Holdings Ltd DARE Dare Bioscience APLS Apellis Pharmaceuticals CABA Cabaletta Bio ELYM Eliem Therapeutics EVO Evotec SE ADR NERV Minerva Neurosciences OTLK OUTLOOK THERAPEUTICS INC RVLP RVL Pharmaceuticals PLC RZLT Rezolute VRDN Viridian Therapeutics MRNS Marinus Pharmaceuticals SCPH Scpharmaceuticals AMAG AMAG Pharmaceuticals ARQT Arcutis Biotherapeutics  BHVN Biohaven Pharmaceutical Holding Co Ltd XENE Xenon Pharmaceuticals IRON Disc Medicine NMRA Neumora Therapeutics ARCT Arcturus Therapeutics Holdings AEON AEON Biopharma VTRS Viatris

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

Since 07-Mar-2019

$5

$1.24 (32.98%)

$18

4 years 8 months 4 days ago
(06-May-2021)

0/6 (0%)

$1.02 (25.63%)

Buy

Since 14-Feb-2019

$12

$8.24 (219.15%)

$10

4 years 10 months 8 days ago
(02-Mar-2021)

2/6 (33.33%)

$8.01 (200.75%)

651

Buy

Since 31-Jul-2019

$15

$11.24 (298.94%)

$19

4 years 11 months 30 days ago
(11-Jan-2021)

0/9 (0%)

$10.93 (268.55%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Douglas Tsao is most bullish on?

Potential upside of $126.51 has been obtained for ARGX (ARGENX NV ADR)

Which stock is Douglas Tsao is most reserved on?

Potential downside of -$1.08 has been obtained for OTLK (OUTLOOK THERAPEUTICS INC)

What Year was the first public recommendation made by Douglas Tsao?

On 2008

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?